Eli Lilly Climbs 3% While the Nasdaq 100 Sheds 1.7%
Lilly traded up 3.07% intraday on 18 August 2026 while the Nasdaq 100 fell 1.72%, a split that puts the rotation-out-of-tech thesis to a same-session test.
Eli Lilly shares rose 3.07% to 1,219.53 as of 18:56 GMT on 18 August 2026, against a 1.72% decline in the Nasdaq 100 tracker QQQ, with GuruFocus attributing the move to rotation out of expensive technology and to record growth in the Mounjaro and Zepbound franchises.
Eli Lilly and Co. (ticker: LLY) was one of the few large-cap names moving the right way on Tuesday. The shares changed hands at 1,219.53 as of the last trade at 18:56 GMT on 18 August 2026, up 3.07% from the prior close of 1,183.16, with an intraday range of 1,192.10 to 1,225.50. The stock spent the session in positive territory even as the broad market went the other way.
That contrast is the story. The Nasdaq 100 tracker QQQ was down 1.72% at $717.32, below its previous close of $729.87 and trading near the bottom of a $715.92–$722.13 band. The S&P 500 proxy SPY fell 0.63% to $767.84. The Dow tracker DIA, the most defensive of the three by construction, gave up just 0.16% to $533.34. Money was not leaving equities wholesale on Tuesday; it was leaving one end of the market.
What the same-session numbers actually show
The rotation argument gets made constantly and is usually impossible to verify in real time. Here it is unusually legible. The gap between the tech-heavy Nasdaq 100 tracker and the Dow tracker ran to roughly 1.6 percentage points on the day — a wide spread for a single session between two large-cap US benchmarks, and a spread that points at composition rather than at a market-wide risk event. Lilly, meanwhile, added about 36 points a share from its prior close.
None of that proves capital moved directly from semiconductors and software into pharmaceuticals. Single sessions are noisy, and a 3% move in a mega-cap can be driven by a single institutional buyer. But the shape of the tape — mega-cap tech down hard, Dow-style industrials and healthcare barely scratched, a healthcare heavyweight up — is what rotation looks like when it happens, rather than what a general de-risking looks like. In a broad flight from equities, Lilly would be down too, just less.
Why Lilly is the natural landing spot
GuruFocus, which flagged the move, ties the strength to two products: Mounjaro, Lilly’s type 2 diabetes treatment, and Zepbound, the same active molecule approved for chronic weight management. Both sit in the GLP-1 class — drugs that mimic a gut hormone to regulate blood sugar and appetite — and both, per the source, are fuelling record growth at the company.
The commercial logic behind the rotation is straightforward for anyone reallocating away from the AI trade. Investors who have spent two years paying up for revenue that is still largely a promise are looking for revenue that already exists, in a category with structural demand, reimbursement pathways forming, and manufacturing capacity as the binding constraint rather than customer appetite. Obesity and diabetes therapeutics currently fit that description better than almost anything else in the large-cap universe.
GuruFocus also notes that its own estimated fair value screen shows Lilly trading below that estimate — a valuation model, not a reported financial figure, and one that should be read as a signal rather than a measurement. Its relevance here is narrow but real: if a name is genuinely being bid because it is cheaper than the thing being sold, a below-fair-value read is at least consistent with that. If the same screen showed a large premium, the rotation story would be harder to tell.
Where the thesis is weakest
Three caveats belong on the same page as the price.
- One day is one day. The Nasdaq 100 tracker’s 1.72% fall is a meaningful move but not a regime change. Rotations that look decisive on a Tuesday afternoon frequently reverse inside a week, particularly when the selling is concentrated in a handful of index-heavy names.
- Lilly is not a defensive stock. It carries a growth multiple because the market is pricing continued expansion in the incretin franchise. That makes it vulnerable to the same discount-rate arithmetic hitting technology, and to competitive, pricing and supply headlines specific to GLP-1s. Investors treating it as a hiding place are buying a different growth story, not the absence of one.
- The move was already fading in size terms. The lead figure cited was a 2.6% gain; the last trade showed 3.07%. Intraday prints on a fast tape are snapshots, and a stock that traded as high as 1,225.50 and as low as 1,192.10 during the session had a real spread of outcomes inside a single day.
What to watch from here
The test of whether Tuesday was rotation or noise is whether the benchmark spread persists. Watch the Nasdaq 100 tracker against the Dow tracker over the coming sessions: if the tech-heavy index keeps underperforming while healthcare and industrials hold up, the flow argument strengthens. If the gap closes quickly, Tuesday was a drawdown in a few crowded names and Lilly’s gain was its own event.
The test of whether Tuesday was rotation or noise is whether the benchmark spread persists.
For Lilly specifically, the variable that matters is the incretin franchise’s growth trajectory, since that is what the current multiple rests on. Anything touching manufacturing throughput, payer coverage of Zepbound, or the competitive field in weight management will move the shares more than any index-level flow. The valuation screen showing a discount to fair value is a starting point for that work, not a conclusion — it is derived from assumptions about future growth that the market is actively repricing.
For portfolio holders, the honest read is narrow: on 18 August 2026, one large-cap pharmaceutical name went up 3.07% while the largest technology index in the world went down 1.72%, and there is a plausible product-level reason why the two happened together. Whether that becomes a trend is a question the next several sessions answer, not this one.
Key facts
- Eli Lilly (LLY): 1,219.53, +3.07%, as of 18:56 GMT 18 Aug 2026
- Nasdaq 100 (QQQ): $717.32, -1.72% on the day
- Growth drivers cited: Mounjaro and Zepbound, described as fuelling record growth
- Valuation signal: GuruFocus estimated fair value shows shares trading below fair value
Frequently asked questions
How much did Eli Lilly stock move on 18 August 2026?
As of the last trade at 18:56 GMT on 18 August 2026, Eli Lilly was quoted at 1,219.53, up 3.07% from the previous close of 1,183.16. The intraday range was 1,192.10 to 1,225.50. GuruFocus, which reported the move earlier in the session, cited a 2.6% gain at the time of writing.
What are Mounjaro and Zepbound?
Both are Eli Lilly products in the GLP-1 class, drugs that mimic a gut hormone regulating blood sugar and appetite. Mounjaro is marketed for type 2 diabetes and Zepbound for chronic weight management. GuruFocus identifies the two franchises as the source of record growth at the company.
Did the broader market fall on the same day?
Yes. The Nasdaq 100 tracker QQQ fell 1.72% to $717.32, the S&P 500 proxy SPY fell 0.63% to $767.84, and the Dow tracker DIA slipped 0.16% to $533.34, all as of 18:56 GMT on 18 August 2026. Technology-heavy exposure took the heaviest losses.
Does one session prove investors are rotating out of technology?
No. A single day’s spread between benchmarks is suggestive, not conclusive. The pattern on 18 August 2026 — mega-cap tech down sharply, the Dow tracker nearly flat, a healthcare heavyweight higher — is consistent with rotation, but rotations often reverse within days. Persistence over multiple sessions is what would confirm it.
What does ‘below estimated fair value’ mean here?
It refers to GuruFocus’s own valuation model, which estimates an intrinsic value for a stock and compares it with the market price. It is a model output based on assumptions about future growth, not a reported financial figure, and should be treated as a screening signal rather than a measurement of what the shares are worth.
Is Eli Lilly a defensive holding?
Not in the conventional sense. The stock carries a growth valuation tied to expectations for continued expansion of its incretin franchise, which leaves it exposed to interest-rate-driven repricing and to competitive, pricing and manufacturing news specific to GLP-1 drugs. Buying it as shelter from tech volatility means buying a different growth story, not less growth risk.
Sources
Photo: Magda Ehlers · Pexels Licence — source
